Get the Stockscreener App
29.79
3.37%
0.97
After Hours:
29.79
Quidelortho Corporation stock is traded at $29.79, with a volume of 1.35M.
It is up +3.37% in the last 24 hours and down -2.87% over the past month.
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.
See More
Previous Close:
$28.82
Open:
$28.43
24h Volume:
1.35M
Relative Volume:
0.94
Market Cap:
$2.09B
Revenue:
$2.76B
Net Income/Loss:
$-358.70M
P/E Ratio:
-5.994
EPS:
-4.97
Net Cash Flow:
$-35.90M
1W Performance:
+3.91%
1M Performance:
-2.87%
6M Performance:
-33.13%
1Y Performance:
-5.82%
1-Day Range:
$28.43
$31.25
1-Week Range:
$27.40
$31.25
52-Week Range:
$23.77
$49.45
Quidelortho Corporation Stock (QDEL) Company Profile
Name
Quidelortho Corporation
Sector
Industry
Phone
(858) 552-1100
Address
9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA
Compare QDEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QDEL
Quidelortho Corporation
|
29.79 | 2.09B | 2.76B | -358.70M | -35.90M | -4.97 |
|
ABT
Abbott Laboratories
|
136.26 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.78 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
396.74 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
88.75 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.18 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Quidelortho Corporation Stock (QDEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-25 | Upgrade | Jefferies | Hold → Buy |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-24 | Initiated | Jefferies | Hold |
| Sep-19-24 | Resumed | UBS | Neutral |
| Sep-05-24 | Upgrade | Craig Hallum | Hold → Buy |
| Mar-04-24 | Downgrade | UBS | Neutral → Sell |
| Feb-14-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-14-22 | Upgrade | UBS | Sell → Neutral |
| Sep-19-22 | Initiated | Citigroup | Neutral |
| Jul-20-22 | Initiated | UBS | Sell |
| Jun-17-22 | Resumed | JP Morgan | Neutral |
| Feb-22-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jan-22-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-12-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-26-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-23-18 | Resumed | Raymond James | Strong Buy |
| Mar-08-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jan-22-18 | Reiterated | Barclays | Overweight |
| Jan-04-18 | Upgrade | CL King | Neutral → Buy |
| Sep-19-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-18-17 | Upgrade | William Blair | Mkt Perform → Outperform |
| Apr-25-17 | Reiterated | Canaccord Genuity | Hold |
| Feb-17-17 | Initiated | CL King | Neutral |
| Dec-16-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-13-16 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-18-16 | Reiterated | Barclays | Overweight |
| Feb-09-16 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jan-08-16 | Reiterated | Canaccord Genuity | Buy |
| Dec-14-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-02-15 | Initiated | Barclays | Overweight |
| Jul-31-13 | Reiterated | Canaccord Genuity | Buy |
| Mar-03-11 | Downgrade | Wedbush | Outperform → Neutral |
View All
Quidelortho Corporation Stock (QDEL) Latest News
What Makes QuidelOrtho (QDEL) a New Buy Stock - Nasdaq
Why QuidelOrtho (QDEL) is a Top Growth Stock for the Long-Term - Yahoo Finance
Should Value Investors Buy QuidelOrtho (QDEL) Stock? - Yahoo Finance
This QuidelOrtho Insider Increased Their Holding In The Last Year - simplywall.st
QuidelOrtho Declares that its Molecular Diagnostics Approach will be Refocused - MSN
Lex seeks FDA clearance ahead of $100M Quidelortho takeover - BioWorld MedTech
QuidelOrtho set to buy LEX Diagnostics for $100m after FDA approval trigger - Cambridge Independent
QuidelOrtho Corp (QDEL) Trading 4% Higher on Jun 9 - GuruFocus
QuidelOrtho seeks FDA approval to complete acquisition of LEX Diagnostics - Mugglehead Magazine
QuidelOrtho (QDEL) Down 18% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Clinical Laboratory Molecular Diagnostics for Infectious Disease Market Research 2025-2029: Biotechnology and Genomics Drive Advancements, Impact of Multiplex Assays in Diagnosis and Treatment - GlobeNewswire Inc.
Transcript : QuidelOrtho Corporation Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 08 - MarketScreener
Transcript : QuidelOrtho Corporation Presents at 45th Annual William Blair Growth Stock Conference, Jun-04-2025 08 - marketscreener.com
QuidelOrtho Corp (QDEL) Stock Price Down 2.92% on Jun 2 - GuruFocus
QuidelOrtho to discontinue Savanna platform development - MSN
QuidelOrtho (QDEL) to Acquire LEX Diagnostics Amid Strategic Shi - GuruFocus
QuidelOrtho shifts focus with LEX Diagnostics deal, drops Savanna By Investing.com - Investing.com South Africa
Transcript : QuidelOrtho CorporationSpecial Call - marketscreener.com
QuidelOrtho Announces Strategy to Accelerate Growth in Molecular Diagnostics | QDEL Stock News - GuruFocus
QuidelOrtho (QDEL) Shifts Strategy, Plans to Acquire LEX Diagnos - GuruFocus
QuidelOrtho to exit Savanna platform development (QDEL:NASDAQ) - Seeking Alpha
QuidelOrtho shifts focus with LEX Diagnostics deal, drops Savanna - Investing.com
QuidelOrtho announces a refocusing of its molecular diagnostics strategy - TipRanks
QuidelOrtho (QDEL) to acquire full ownership of LEX Diagnostics, announces strategy to accelerate growt - StreetInsider
QuidelOrtho Makes Major Molecular Diagnostics Pivot: $100M LEX Acquisition to Replace Savanna Platform - Stock Titan
Why QuidelOrtho (QDEL) is a Top Momentum Stock for the Long-Term - sharewise
Here's Why QuidelOrtho (QDEL) is a Strong Growth Stock - Yahoo Finance
QuidelOrtho Corp (QDEL) Stock Price Down 3.63% on May 29 - GuruFocus
QuidelOrtho Stockholders Approve Equity Plan Changes - TipRanks
Luxfer, LGI Homes, QuidelOrtho, Dentsply Sirona, and AdaptHealth Stocks Trade Up, What You Need To Know - Yahoo Finance
10,269 Shares in QuidelOrtho Co. (NASDAQ:QDEL) Acquired by BNP Paribas Financial Markets - Defense World
QuidelOrtho’s SWOT analysis: diagnostics firm’s stock faces pivotal year - Investing.com
QuidelOrtho’s SWOT analysis: diagnostics firm’s stock faces pivotal year By Investing.com - Investing.com Canada
Asian Hospital, Faridabad Becomes the First in the City to Launch Total Lab Automation with QuidelOrtho - APN News
QuidelOrtho to Participate in Upcoming June 2025 Investor Conferences - BioSpace
QuidelOrtho to Participate in Upcoming Investor Conferences | QDEL Stock News - GuruFocus
Asian Hospital, Faridabad introduces total lab automation with QuidelOrtho - IndiaMedToday
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now - MSN
QuidelOrtho Management to Present at William Blair and Jefferies Healthcare Conferences Next Month - Stock Titan
Asian Hospital in Faridabad launches total lab automation in partnership with QuidelOrtho - BioSpectrum India
QuidelOrtho Corp (QDEL) Stock Price Down 3.32% on May 19 - GuruFocus
Captrust Financial Advisors Boosts Holdings in QuidelOrtho Co. (NASDAQ:QDEL) - Defense World
Ameriprise Financial Inc. Has $10.84 Million Holdings in QuidelOrtho Co. (NASDAQ:QDEL) - Defense World
Quidelortho Corporation Stock (QDEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Quidelortho Corporation Stock (QDEL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Blaser Brian J. | President and CEO |
Dec 11 '24 |
Buy |
41.42 |
6,033 |
249,878 |
6,033 |
4.52%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):